Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas

M Peña; C Montané; A Paviglianiti; L Hurtado; S González; I Carro; C Maluquer; E Domingo-Domenech; E Gonzalez-Barca; A Sureda; A Mussetti

doi:10.1038/s41409-023-02069-2

Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas

Bone Marrow Transplant. 2023 Nov;58(11):1282-1285. doi: 10.1038/s41409-023-02069-2. Epub 2023 Aug 25.

Authors

M Peña^{1

2}, C Montané^{1

2}, A Paviglianiti^{1

2}, L Hurtado¹, S González¹, I Carro^{1

2}, C Maluquer^{1

2}, E Domingo-Domenech^{1

2}, E Gonzalez-Barca^{1

2

3}, A Sureda^{1

2

3}, A Mussetti^{4

5}

Affiliations

¹ Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.
² Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
³ Bellvitge Health Sciences Campus, University of Barcelona, Barcelona, Spain.
⁴ Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain. amussetti@iconcologia.net.
⁵ Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain. amussetti@iconcologia.net.

PMID: 37626265
DOI: 10.1038/s41409-023-02069-2

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Bispecific* / therapeutic use
Hematopoietic Stem Cell Transplantation*
Humans
Lymphoma, Non-Hodgkin* / therapy
Transplantation Conditioning

Substances

Antibodies, Bispecific